TipRanks on MSN

AlphaTON, Cyncado recaps preclinical mesothelioma data

AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, issued a recap of data presented on Saturday at the AACR-NCI-EORTC ...
TMCnet

AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a human epithelioid mesothelioma cell line, ...

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

MSD receives FDA approval for Winrevair’s updated indication

MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for ...
GlobalData on MSN

BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment

The European Commission has approved BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy as a ...
Business Wire

Seismic Therapeutic Presents New Preclinical Data for S-4321, a Next Generation PD‑1:FcγRIIb-Selective Bifunctional Agonist Antibody for the Treatment of Autoimmune Disease ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new data for S-4321, its next generation PD‑1: ...
BioWorld

Human, mouse PD-1 differ inside and out

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...